Analyst Research
| Report Title | Price |
|---|---|
|
Provider: Thomson Reuters Stock Report
|
$25.00
|
|
Provider: ValuEngine, Inc.
|
$196.00
|
|
Trading Report for (ABT). A detailed report, including free correlated market analysis, and updates.
Provider: Stock Traders Daily
|
$58.00
|
|
Provider: Stock Traders Daily
|
$495.00
|
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
Abbott Laboratories Completes Separation Of Research-Based Pharmaceuticals Business
Abbott Laboratories announced it has completed the separation of its research-based pharmaceuticals business, which became AbbVie, a new independent biopharmaceutical company. AbbVie will begin trading independently on the New York Stock Exchange January 02, 2013 under the symbol ABBV.
Latest Developments for Abbott Laboratories
- Abbott Laboratories Announces CE Mark For Coronary Drug Eluting Stent
- Russia Rejects Abbott Laboratories Plan To Buy Petrovax-Reuters
- Abbott Laboratories Announces FDA Approval And U.S. Launch Of TECNIS Toric Intraocular Lens For Cataract Patients
- Abbott Laboratories Issues Q2 2013 EPS Guidance In Line With Analysts' Estimates; Reaffirms FY 2013 EPS Guidance
Latest Key Developments in Pharmaceuticals
- Nattopharma ASA Maintains FY 2013 Revenue Guidance
- Grifols SA’s Study Demonstrates Higher Dose Of PROLASTIN-C Increases Levels Of Alpha1-PI To Within Normal Range In Patients With AAT Deficiency-DJ
- Protalex Inc Announces Positive Interim Review of Phase 1b Trial Of PRTX-100 in Rheumatoid Arthritis By Independent Data Safety Monitoring Committee
- Pfizer Inc Announces Plan For Split-Off Of Zoetis Inc
- Share this
- Link this
- Digg this
Follow Reuters